Abcam, ab108830, Factor VII Activity Assay Kit (Human, Colorimetric)

Size: 100Test
Factor VII Activity Assay Kit (Human, Colorimetric) (ab108830) has been developed to determine human FVII activity in plasma, serum and cell culture supernatants.
Key facts
Detection method:Colorimetric,
Sample types:Plasma, Cell culture supernatant, Serum,
Reacts with:Human,
Assay type:Enzyme activity (quantitative),
Sensitivity:= 4 mIU/mL,
Range:0.0125 - 0.2 IU/mL,
Assay time:3h,
Assay Platform:Microplate reader

Product details:
Factor VII Activity Assay Kit (Human, Colorimetric) (ab108830) has been developed to determine human FVII activity in plasma, serum and cell culture supernatants.
Factor VII assay principle
This assay uses a combined immunoassay / indirect amidolytic assay method.
A polyclonal antibody specific for Human FVII has been pre-coated onto a microplate and active FVII is bound to the immobilized antibody. The assay then measures the ability of lipoprotein TF/FVIIa to activate factor X (FX) to factor Xa.
The amidolytic activity of the TF/FVIIa complex is quantitated by the amount of FXa produced using a highly specific FXa substrate releasing a yellow para-nitroaniline (pNA) chromophore. The change in absorbance of the pNA at 405 nm is directly proportional to the FVII enzymatic activity.
Other Notes
This product was previously called Factor VII Human Chromogenic Activity Assay Kit.
Factor VII (FVII) is a vitamin K-dependent plasma glycoprotein that is synthesized in the liver and circulates in blood as a single-chain inactive zymogen with a molecular mass of 50 kDa. Upon tissue damage and vascular injury, the cell surface receptor and cofactor tissue factor (TF) binds and allosterically activates FVII to its active form, FVIIa. The TF/FVIIa complex catalyzes the conversion of both factor IX to factor IXa and factor X to factor Xa to initiate coagulation via the extrinsic pathway. Very low levels of FVII are associated with severe coagulation disorders. Elevated plasma levels of FVII coagulant activity constitute an independent risk factor for fatal outcomes of coronary heart disease in middle-aged men.

Properties and Storage Information:
Shipped at conditions-Blue Ice, Appropriate short-term storage conditions--20°C, Appropriate long-term storage conditions-Multi, Storage information-Please refer to protocols

Supplementary Information:
This supplementary information is collated from multiple sources and compiled automatically.
Factor VII also known as factor 7 or factor seven is a plasma glycoprotein with a molecular mass of approximately 50 kDa. It plays an important role in the blood coagulation process. Factor VII is mainly produced in the liver and requires vitamin K for its synthesis. In the inactive form it circulates in the plasma but upon activation to factor 7a it initiates the extrinsic pathway of blood coagulation. This activation is a critical step in hemostasis which helps to prevent excessive bleeding.
Biological function summary
Factor 7a indirectly activates further components in the blood coagulation cascade. Upon activation factor 7a becomes a part of the tissue factor (TF) complex which includes tissue factor expressed on subendothelial cells. The complex triggers the activation of factor IX and factor X propagating the coagulation cascade downstream. This series of activations amplifies the signal for clot formation highlighting factor VII's integral role in initiating coagulation.
Pathways
Factor VII is primarily involved in the extrinsic pathway of the coagulation cascade. This pathway is initiated when factor 7a forms a complex with tissue factor a protein that becomes exposed at injury sites. Factor VII is also indirectly linked to the common coagulation pathway through activation of factor X. The interaction between these pathways ensures efficient and rapid clot formation. Additionally factor IX also interacts with factor VII in the intricate network of coagulation processes that sustain hemostasis.
Deficiencies or dysfunctions in factor VII can lead to coagulopathies such as congenital factor VII deficiency which results in excessively prolonged bleeding. Conversely elevated factor VII activity can contribute to thromboembolic disorders like myocardial infarction. In these conditions factor VII often interacts with proteins like factor X and tissue factor highlighting their clinical significance in managing blood coagulation abnormalities.